Condition
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast clinical trials and research
As of November 12, 2026, Find a Trial lists 4 Human Epidermal Growth Factor 2 Negative Carcinoma of Breast clinical trials that are recruiting, at sites in 4 countries (most in United States (3), Nigeria (1), Australia (1)). By phase: Phase 2 (2), Phase 1/2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 4Countries
Newest Human Epidermal Growth Factor 2 Negative Carcinoma of Breast clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Capecitabine with or without elacestrant for ER-positive advanced breast cancer | Phase 2 | Boston, Massachusetts | Recruiting | Oct 29, 2025 |
| Evaluating NKT3964 for Adults with Advanced Solid Tumors | Phase 1 | Little Rock, Arkansas and 20 other locations | Recruiting | Sep 19, 2024 |
| Testing anti-HER2 treatment before and after surgery for Nigerian women with HER2+ breast cancer | Phase 2 | Ikeja, Lagos and 3 other locations | Recruiting | Apr 4, 2024 |
| Evaluating INX-315 for advanced cancer treatment | Phase 1/2 | Orlando, Florida and 17 other locations | Recruiting | Feb 21, 2023 |
All recruiting trials (4)
-
Capecitabine with or without elacestrant for ER-positive advanced breast cancer
This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.
-
Evaluating NKT3964 for Adults with Advanced Solid Tumors
This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.
-
Testing anti-HER2 treatment before and after surgery for Nigerian women with HER2+ breast cancer
This study will test whether giving anti-HER2 drugs with chemotherapy before and after surgery helps Nigerian women with HER2-positive breast cancer.
-
Evaluating INX-315 for advanced cancer treatment
This study is testing a new oral medication called INX-315 to see if it can safely help people with advanced cancers, including breast and ovarian cancer, who haven't responded to other treatments.
Related topics
Quick answers
How many Human Epidermal Growth Factor 2 Negative Carcinoma of Breast clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (3 trials), Nigeria (1 trial), Australia (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.